Graham Capital Management L.P. Has $1.16 Million Holdings in Genmab A/S (NASDAQ:GMAB)

Graham Capital Management L.P. increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,417 shares of the company's stock after purchasing an additional 15,321 shares during the period. Graham Capital Management L.P.'s holdings in Genmab A/S were worth $1,157,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC boosted its stake in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC boosted its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Truist Financial cut their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Up 1.2%

Shares of GMAB stock traded up $0.23 on Friday, reaching $19.88. The stock had a trading volume of 836,564 shares, compared to its average volume of 1,112,041. The firm's 50-day moving average is $19.74 and its two-hundred day moving average is $20.74. The firm has a market capitalization of $12.75 billion, a price-to-earnings ratio of 11.43, a P/E/G ratio of 2.65 and a beta of 1.04. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.06.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.